VasQ and A
The FDA has approved VasQ, a new device to reduce fistula failure, for a 2-year clinical trial with 129 patients. The device keeps fistulas from growing too large by providing an external support.
Read the full article » | Posted 08-17-2017
Related Articles
- Global Wearable Artificial Kidney Market Expected to Grow Posted 07-12-2024
- Byonyks X1: a New, Small, Portable APD Machine Posted 06-14-2024
- The Public-Private ASN, DHSS, KidneyX Partnership is 5 Years Old This Year Posted 05-09-2024
- New Measure of Home Dialysis Dropout Posted 01-16-2024